PCRX
Pacira BioSciences Inc.
$26.46
-$0.20(-0.75%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$1.23B
Volume
330.95K
52W Range
$13.79 - $27.64
Target Price
$29.00
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $249.0M | $276.4M | $286.6M | $3.0M | $421.0M | $429.6M | $541.5M | $666.8M | $657.0K | $304.0K | ||
| Total Revenue | $244.5M | $270.1M | $284.3M | $337.3M | $421.0M | $429.6M | $541.5M | $666.8M | $657.0K | $701.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-71.8M | $-110.1M | $-87.9M | $-86.8M | $106.7M | $117.3M | $140.3M | $199.3M | $184.7M | $170.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $177.2M | $166.3M | $198.7M | $-83.8M | $314.3M | $312.3M | $401.3M | $467.5M | $-184.0M | $530.5M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-239.5M | $-308.4M | $-311.6M | $-321.4M | $278.6M | $260.8M | $268.4M | $396.6M | $403.0M | $433.0M | ||
| Research & Development | $28.7M | $45.7M | $57.3M | $55.7M | $72.1M | $59.4M | $55.5M | $84.8M | $76.3M | $81.6M | ||
| Research Expense | $28.7M | $45.7M | $57.3M | $55.7M | $72.1M | $59.4M | $55.5M | $84.8M | $76.3M | $81.6M | ||
| Selling, General & Administrative | $139.0M | $152.6M | $161.5M | $177.3M | $200.8M | $193.5M | $199.3M | $254.5M | $269.4M | $294.1M | ||
| Selling & Marketing Expenses | $139.0M | $152.6M | $161.5M | $177.3M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-5.7M | $-6.0M | $-7.5M | $-9.0M | $200.8M | $193.5M | $199.3M | $254.5M | $269.4M | $294.1M | ||
| Salaries & Wages | $-33.4M | $-31.2M | $-31.6M | $-31.7M | $33.6M | $-8.6M | $-9.0M | $-10.2M | $-10.2M | $-10.5M | ||
| Depreciation & Amortization | $-11.2M | $-12.8M | $-13.8M | $-13.2M | $5.7M | $7.9M | $13.6M | $57.3M | $57.3M | $57.3M | ||
| Depreciation & Amortization | $-11.2M | $-12.8M | $-13.8M | $-13.2M | $5.7M | $7.9M | $13.6M | $57.3M | $57.3M | $57.3M | ||
| Amortization | $-4.4M | $-4.2M | $-10.4M | $-12.8M | $5.7M | $7.9M | $13.6M | $57.3M | $57.3M | $57.3M | ||
| Other Operating Expenses | $71.0K | $-308.4M | $-311.6M | $1.6M | $7.9M | $12.2M | $-4.3M | $-827.0K | $-553.0K | $-1.5M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $9.4M | $-32.0M | $-20.1M | $-318.4M | $10.5M | $46.4M | $89.9M | $60.0M | $87.7M | $-73.4M | ||
| EBITDA | $25.9M | $-13.3M | $1.1M | $49.1M | $56.1M | $63.5M | $113.9M | $147.6M | $161.3M | $35.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $7.7M | $7.1M | $18.0M | $21.9M | $23.6M | $23.5M | $29.0M | $35.6M | $20.3M | $16.6M | ||
| Intinc | $678.0K | $1.3M | $4.1M | $6.5M | $7.4M | $4.6M | $896.0K | $4.5M | $11.4M | $19.7M | ||
| Net Non-Operating Interest Income/Expense | $-7.0M | $-5.7M | $-14.0M | $-15.5M | $-16.3M | $-21.0M | $-30.9M | $-35.4M | $11.4M | $19.7M | ||
| Gain on Sale of Securities | -- | -- | -- | $900.0K | $5.7M | -- | $2.6M | -- | -- | -- | ||
| Other Income/Expense | $217.0K | $82.0K | $3.5M | $-333.4M | $5.0M | $122.5M | $2.7M | $-22.2M | $17.1M | $-7.1M | ||
| Other Special Charges | $-217.0K | $-82.0K | $-3.5M | $333.4M | $-5.0M | $-5.2M | $-2.7M | $-11.3M | $-17.1M | $7.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | $-303.0K | $-100.0K | $106.7M | $-38.0K | -- | -- | $1.1M | $8.5M | ||
| Special Income Charges | -- | -- | $303.0K | $100.0K | $-106.7M | $-117.3M | -- | -- | $-1.1M | $-163.2M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $163.2M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $9.8M | $-30.8M | $-24.4M | $21.5M | $21.1M | $43.6M | $85.4M | $48.9M | $82.0M | $-46.5M | ||
| Pre-Tax Income | $2.1M | $-37.8M | $-42.5M | $-425.0K | $-10.7M | $20.1M | $56.4M | $13.3M | $61.7M | $-63.1M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $264.0K | $105.0K | $140.0K | $46.0K | $268.0K | $-125.4M | $14.4M | $-2.6M | $19.7M | $36.5M | ||
| NET INCOME | ||||||||||||
| Net Income | $1.9M | $-37.9M | $-42.6M | $-471.0K | $-11.0M | $145.5M | $42.0M | $15.9M | $42.0M | $-99.6M | ||
| Net Income (Continuing Operations) | $1.9M | $-37.9M | $-42.6M | $-471.0K | $-11.0M | $145.5M | $42.0M | $15.9M | $42.0M | $-99.6M | ||
| Net Income (Discontinued Operations) | $1.9M | $-37.9M | $-42.6M | $-471.0K | $-11.0M | $145.5M | $42.0M | $15.9M | $42.0M | $-99.6M | ||
| Net Income (Common Stockholders) | $1.9M | $-37.9M | $-42.6M | $-471.0K | $39.4M | $145.5M | $42.0M | $15.9M | $42.0M | $-99.6M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $107.0M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-311.4M | $-418.5M | $-399.5M | $-408.2M | $385.3M | $378.1M | $408.7M | $595.9M | $587.7M | $603.4M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $36.5M | $37.2M | $39.8M | $40.9M | $41.5M | $42.7M | $44.3M | $45.5M | $46.2M | $46.2M | ||
| Average Shares Outstanding (Diluted) | $41.3M | $37.2M | $39.8M | $40.9M | $41.5M | $43.7M | $45.6M | $46.5M | $52.0M | $46.2M | ||
| Shares Outstanding | $37.1M | $37.5M | $40.7M | $41.2M | $42.0M | $43.9M | $44.8M | $46.0M | $46.5M | $46.3M | ||
| Basic EPS | $0.05 | $-1.02 | $-1.07 | -- | $-0.27 | $3.41 | $0.95 | $0.35 | $0.91 | $-2.15 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.27 | $3.41 | $0.95 | $0.35 | $0.91 | $-2.15 | ||
| Diluted EPS | $0.04 | $-1.02 | $-1.07 | $-0.01 | $-0.27 | $3.33 | $0.92 | $0.34 | $0.89 | $-2.15 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | $3.33 | $0.92 | $0.34 | $0.89 | $-2.15 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-2.2M | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | $-4.9M | $-1.6M | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | $8.2M | $-2.4M | $-3.9M | $-4.1M | $-3.5M | $-2.1M | ||
| Loss And Loss Adjustment Expected Incurred | -- | -- | -- | -- | -- | -- | $140.3M | -- | -- | -- | ||
| Net Income Discontinuous Operations | -- | -- | $-4.9M | $1.6M | $752.0K | $-200.0K | -- | -- | -- | -- | ||
| Non Recurring Operation Expense | -- | -- | -- | -- | $-3.5M | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | $-200.0K | $-200.0K | -- | -- | -- | -- | ||
| Other Gand A | $-5.7M | $-6.0M | $-7.5M | $-9.0M | $200.8M | $193.5M | $199.3M | $254.5M | $269.4M | $294.1M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | $140.3M | $26.1M | -- | -- | ||
| Rent And Landing Fees | $-5.7M | $-6.0M | $-7.5M | $-7.2M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $139.0M | $152.6M | $161.5M | $177.3M | -- | -- | -- | -- | -- | -- | ||
| Write Off | -- | -- | -- | -- | -- | $117.3M | -- | -- | -- | -- | ||
| Othspecchg | -- | -- | -- | -- | $-2.5M | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | $-303.0K | $-100.0K | $106.7M | $-38.0K | -- | -- | $1.1M | $8.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PCRX | $26.46 | -0.8% | 330.95K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |